Advanced Solid Tumors Clinical Trials

72 studies are recruiting for advanced solid tumors in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

   This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in part…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Cancer Center, Duarte, California

   Locations

   47 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT06004245 on ClinicalTrials.gov

2. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07349537 on ClinicalTrials.gov

3. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

   The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Colorado Denver, Aurora, Colorado

   Locations

   9 in total

   Run by

   Accent Therapeutics

   See if you can join NCT06799065 on ClinicalTrials.gov

4. A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

   This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center ( Site 0261), Tampa, Florida

   Locations

   75 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05067283 on ClinicalTrials.gov

5. A Study of BG-C477 in Participants With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Phoenix Cancer Center, Goodyear, Arizona

   Locations

   59 in total

   Run by

   BeOne Medicines

   See if you can join NCT06596473 on ClinicalTrials.gov

6. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

   The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   20 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06657222 on ClinicalTrials.gov

7. A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

   Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main g…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Alabama at Birmingham ( Site 1005), Birmingham, Alabama

   Locations

   49 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06818643 on ClinicalTrials.gov

8. A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

   The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-428 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University Medical Center, Palo Alto, California

   Locations

   8 in total

   Run by

   FoRx Therapeutics AG

   See if you can join NCT07356453 on ClinicalTrials.gov

9. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

   The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville, North Carolina

   Locations

   9 in total

   Run by

   EMD Serono Research & Development Institute, Inc.

   See if you can join NCT07360314 on ClinicalTrials.gov

10. Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

    The purpose of this trial is to learn about the safety and effectiveness of the antibody GEN1079 in participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1079 to find out if it is safe and determine what are the best doses t…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale University, New Haven, Connecticut

    Locations

    12 in total

    Run by

    Genmab

    See if you can join NCT07387068 on ClinicalTrials.gov

11. Study of FID-022 in Participants With Advanced Solid Tumors

    The goal of this Phase I Clinical Trial is to evaluate the safety and tolerability of FID-022 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    3 in total

    Run by

    Fulgent Pharma LLC.

    See if you can join NCT06694480 on ClinicalTrials.gov

12. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn how wel…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope - Duarte Cancer Center, Duarte, California

    Locations

    54 in total

    Run by

    Bayer

    See if you can join NCT06760819 on ClinicalTrials.gov

13. Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

    The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California San Diego, San Diego, California

    Locations

    22 in total

    Run by

    Pyxis Oncology, Inc

    See if you can join NCT06795412 on ClinicalTrials.gov

14. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

    Stage

    Phase 2

    Ages

    12 and older

    Site

    University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama

    Locations

    181 in total

    Run by

    American Society of Clinical Oncology

    See if you can join NCT02693535 on ClinicalTrials.gov

15. A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

    The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with stand…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Huntersville, North Carolina

    Locations

    11 in total

    Run by

    AstraZeneca

    See if you can join NCT07161414 on ClinicalTrials.gov

16. First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

    This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    12 in total

    Run by

    VelaVigo Bio Inc

    See if you can join NCT07700160 on ClinicalTrials.gov

17. A Study of JNJ-87890387 for Advanced Solid Tumors

    The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Start Midwest, Grand Rapids, Michigan

    Locations

    6 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT06178614 on ClinicalTrials.gov

18. Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

    Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer l…

    Stage

    Phase 1

    Ages

    12 to 120

    Site

    University of Kansas, Fairway, Kansas

    Locations

    2 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT04222413 on ClinicalTrials.gov

19. A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

    This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Scottsdale, Arizona

    Locations

    7 in total

    Run by

    Samsung Bioepis Co., Ltd.

    See if you can join NCT07524348 on ClinicalTrials.gov

20. A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Los Angeles, LLC, Los Angeles, California

    Locations

    33 in total

    Run by

    CStone Pharmaceuticals

    See if you can join NCT06741644 on ClinicalTrials.gov

21. A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

    This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The first medical center of PLA general hospital, Beijing, Beijing Municipality

    Locations

    17 in total

    Run by

    NextCure, Inc.

    See if you can join NCT06792552 on ClinicalTrials.gov

22. Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

    The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors. The primary objectives of this study are to: * To assess the safety and tolerability of …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    8 in total

    Run by

    Gilead Sciences

    See if you can join NCT06167317 on ClinicalTrials.gov

23. Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

    This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado

    Locations

    21 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT06384352 on ClinicalTrials.gov

24. A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

    The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processe…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale Cancer Center, New Haven, Connecticut

    Locations

    14 in total

    Run by

    Ottimo Pharma Limited

    See if you can join NCT07266428 on ClinicalTrials.gov

25. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Precision NextGen Oncology & Research Center, Beverly Hills, California

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov